Kalbitor, ecallantide, approved for treating hereditary angioedema
FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema – The U.S. Food and Drug Administration approved Kalbitor (ecallantide) to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).